bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
Patients at the greatest risk for secondary infections, particularly infections that are resistant to first-line antibiotics, include people who are already vulnerable due to other conditions and diseases—like COVID-19. Because of that, antimicrobial resistance poses a significant additional threat, especially as healthcare systems become overburdened.
Researchers from MIT and Harvard developed a new approach to antibiotic discovery using a type of artificial AI called deep learning. So far, their model has identified eight antibacterial compounds that differ in structure from known antibiotics.
EM combined with good manufacturing practices and risk assessment programs would enhance product safety and reduce consumer risk.
Here at bioMérieux Connection, and throughout bioMérieux, Inc., we’ve been thinking a lot about our mission and what we hope to accomplish in 2020 and beyond.
Patients at the greatest risk for secondary infections, particularly infections...
With the COVID-19 pandemic having reached over 170 countries, and...